Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?—Insights from an international population‐based study
Journal of the European Academy of Dermatology and Venereology · 2024-02 · 38 (2) · 315-324
DOI: 10.1111/jdv.19520 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 04.10.2023. Verfasst von Khalaf Kridin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Lűbeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany. Hauptthemen laut MEDLINE: Antirheumatic Agents, Psoriasis, Melanoma. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Cancer risk after long‐term exposure to interleukin (IL)‐23 inhibitors (IL‐23i) and IL‐17 inhibitors (IL‐17i) remains to be delineated.
Objective
To evaluate the risk of malignancies in patients with psoriasis treated with IL‐23i and IL‐17i relative to those prescribed tumour necrosis factor inhibitors (TNFi) during the first 5 years following drug initiation.
Methods
A global population‐based cohort study included two distinct analyses comparing patients with psoriasis under different therapeutic modalities; (i) new users of IL‐17i(n = 15,331) versus TNFi ( n = 15,331) and (ii) new users of IL‐23i ( n = 5832) versus TNFi ( n = 5832).
Results
Patients prescribed IL‐17i experienced a decreased risk of non‐Hodgkin lymphoma (NHL; HR, 0.58; 95% CI, 0.40–0.82; p = 0.002), colorectal cancer (HR, 0.68; 95% CI, 0.49–0.95; p = 0.024), hepatobiliary cancer (HR, 0.68; 95% CI, 0.58–0.80; p < 0.001), ovary cancer (HR, 0.48; 95% CI, 0.29–0.81; p = 0.005), melanoma (HR, 0.52; 95% CI, 0.37–0.73; p < 0.001), and basal cell carcinoma (BCC; HR, 0.57; 95% CI, 0.48–0.67; p < 0.001). IL‐23i was associated with a reduced risk of NHL (HR, 0.39; 95% CI, 0.19–0.78; p = 0.006), hepatobiliary cancer (HR, 0.44; 95% CI, 0.31–0.62; p < 0.001) and BCC (HR, 0.76; 95% CI, 0.57–0.99; p = 0.046). In a sensitivity analysis comparing patients managed by IL‐17i and IL‐23i with their biologic‐naïve counterparts, these classes were associated with decreased risk of several malignancies.
Conclusion
IL‐17i and IL‐23i are associated with decreased risk of several malignancies. These findings should be considered prior to the prescription of biologics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Lűbeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
- Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
- Unit of Dermatology and Skin Research Laboratory, Galilee Medical Center, Nahariya, Israel.
- School of Medicine, Royal College of Surgeons in Ireland, Busaiteen, Bahrain.
- Department of Dermatology, University of Lübeck, Lübeck, Germany.
- Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany.
ORCID-Profile: Khalaf Kridin
Zitieren
APA
Kridin, K., Abdelghaffar, M., Mruwat, N., Ludwig, R. J., & Thaçi, D. (2024). Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?—Insights from an international population‐based study. Journal of the European Academy of Dermatology and Venereology, 38(2), 315-324. https://doi.org/10.1111/jdv.19520
Vancouver
Kridin K, Abdelghaffar M, Mruwat N, Ludwig RJ, Thaçi D. Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?—Insights from an international population‐based study. Journal of the European Academy of Dermatology and Venereology. 2024;38(2):315-324. doi:10.1111/jdv.19520
BibTeX
@article{Kridin2024,
author = {Kridin, Khalaf and Abdelghaffar, Mariam and Mruwat, Noor and Ludwig, Ralf J and Thaçi, Diamant},
title = {Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?—Insights from an international population‐based study},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2024},
volume = {38},
number = {2},
pages = {315--324},
doi = {10.1111/jdv.19520}
}
EUVIMED